Skip to main content
. Author manuscript; available in PMC: 2015 Jul 24.
Published in final edited form as: Clin Cancer Res. 2014 Nov 11;21(2):357–364. doi: 10.1158/1078-0432.CCR-14-1374

Table 3.

Univariate and multivariate analyses on factors affecting PFS in patients who received cetuximab monotherapy (cohort 5)

Variables Univariate analysis1 Multivariate analysis2
Patient
No.		 PFS
(median,
days)		 6-month
progression-
free rate (%)		 P-
value		 HR 95% CI P-
value
Age3
< 70 years 54 59 18.5% - - - -
  ≥ 70 years 24 60 8.3% 0.227 - - -
Gender
  Male 44 61 22.7% - 1.00 - -
  Female 36 58 5.6% 0.009 1.65 0.98–2.78 0.062
KRAS status4
  Wild type 43 61 20.9% - 1.00 - -
  Mutant 27 59 3.7% 0.142 1.27 0.75–2.14 0.375
YAP1 status
  IYCC 57 61 19.3% - 1.00 - -
  AYCC 23 57 4.3% 0.005 1.82 1.05–3.16 0.034
1

In univariate analyses, log-rank tests were conducted.

2

In multivariate Cox proportional hazard model, variables with P < 0.15 in univariate analysis were only included and the ‘enter method’ was applied. In this multivariate analysis, 70 patients from cohort 6 without missing data on KRAS status were included.

3

Data on age of 2 patients were missing.

4

Data on KRAS mutational status of 10 patients were missing

#

Abbreviations: PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; IYCC, inactivated YAP1 colorectal cancer; AYCC; activated YAP1 colorectal cancer